Analyzing the impact of molecular testing on the cytological diagnosis of thyroid nodules: Insights from our institution's experience
Cancer Cytopathology · 2025
DOI: 10.1002/cncy.70051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cytopathology, 2025. Verfasst von Dokpe Y Emechebe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, School of Medicine, Emory University Hospital, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Thyroid Nodule, Thyroid Neoplasms, Molecular Diagnostic Techniques, Adenocarcinoma, Follicular. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background
Fine‐needle aspiration cytology (FNAC) is a preferred method for evaluation of thyroid nodules. Under The Bethesda System for Reporting Thyroid Cytopathology, approximately 15%–30% of FNAC results fall into an indeterminate category: atypia of undetermined significance (AUS), follicular neoplasm (FN), and suspicious for malignancy (SFM), Bethesda classes III, IV, and V respectively. Molecular testing of indeterminate nodules helps evaluate the risk of malignancy and guide management decisions. This retrospective study assesses the impact of molecular testing on thyroid nodule classification in our institution, with an emphasis on indeterminate results.
Methods
A 9‐year retrospective analysis (January 2015–December 2023) was conducted at the University of North Carolina Health System. FNAC cases were classified per The Bethesda System. Molecular testing results and, when available, surgical pathology outcomes were reviewed. The study compared pre‐ and post‐implementation data of routine reflex molecular testing of thyroid nodule diagnosis.
Results
A total of 3992 thyroid aspirates were evaluated: 490 (12.3%) nondiagnostic (class I), 2096 (52.5%) benign (class II), 1041 (26.1%) AUS (class III), 136 (3.4%) FN (class IV), 89 (2.2%) SFM (class V), and 140 (3.5%) malignant (class VI). Indeterminate cytology (classes III–V) accounted for 32% of all aspirates ( n = 1266). Before molecular testing, the AUS rate was 19.8% with an AUS:malignant ratio of 5.4. Post‐implementation, the AUS rate rose to 30.1%, with a ratio of 8.9. This increase was statistically significant ( p = .029).
Conclusion
Implementation of molecular testing was associated with a significant rise in indeterminate cytologic diagnoses, particularly AUS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, School of Medicine, Emory University Hospital, Atlanta, Georgia, USA.
- Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Department of Pathology and Laboratory Medicine, Section of Cytology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
ORCID-Profile: Dokpe Y Emechebe
Zitieren
APA
Emechebe, D. Y., Patil, S. A., Collins, T., Zhu, L. C., Silverman, J. F., & Dodd, L. G. (2025). Analyzing the impact of molecular testing on the cytological diagnosis of thyroid nodules: Insights from our institution's experience. Cancer Cytopathology. https://doi.org/10.1002/cncy.70051
Vancouver
Emechebe DY, Patil SA, Collins T, Zhu LC, Silverman JF, Dodd LG. Analyzing the impact of molecular testing on the cytological diagnosis of thyroid nodules: Insights from our institution's experience. Cancer Cytopathology. 2025. doi:10.1002/cncy.70051
BibTeX
@article{Emechebe2025,
author = {Emechebe, Dokpe Y and Patil, Sushant A and Collins, Timothy and Zhu, Lee-Ching and Silverman, Jan F and Dodd, Leslie G},
title = {Analyzing the impact of molecular testing on the cytological diagnosis of thyroid nodules: Insights from our institution's experience},
journal = {Cancer Cytopathology},
year = {2025},
doi = {10.1002/cncy.70051}
}
EUVIMED